Directly Observed Hepatitis C Treatment in Methadone Clinics
Status: | Completed |
---|---|
Conditions: | Hepatitis |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 7/11/2015 |
Start Date: | October 2007 |
End Date: | March 2013 |
Contact: | Alain Litwin, MD, MPH |
Email: | alitwin@montefiore.org |
Phone: | 718-944-3862 |
Drug users account for a disproportionately large burden of hepatitis C virus (HCV)
infection. However, HCV treatment adherence rates in drug users may be suboptimal in
patients who use drugs regularly during HCV treatment. Because HCV treatment is most
effective when patients adhere to at least 80% of the prescribed treatment regimen,
interventions to improve HCV treatment adherence need to be developed and evaluated. The
investigators designed the HCV DOT trial to test the efficacy of two versions of modified
directly observed HCV therapy provided on-site at a methadone clinic. The primary objective
of this trial is to determine whether enhanced DOT with both pegylated interferon alfa-2a
plus ribavirin (PEG/RBV-DOT) is more efficacious than standard DOT with weekly
provider-administered pegylated interferon (PEG-DOT) and self-administered ribavirin for
increasing adherence and improving HCV treatment outcomes. The investigators hypothesize
that PEG/RBV-DOT is associated with increased adherence and rates of sustained viral
response compared with PEG-DOT.
infection. However, HCV treatment adherence rates in drug users may be suboptimal in
patients who use drugs regularly during HCV treatment. Because HCV treatment is most
effective when patients adhere to at least 80% of the prescribed treatment regimen,
interventions to improve HCV treatment adherence need to be developed and evaluated. The
investigators designed the HCV DOT trial to test the efficacy of two versions of modified
directly observed HCV therapy provided on-site at a methadone clinic. The primary objective
of this trial is to determine whether enhanced DOT with both pegylated interferon alfa-2a
plus ribavirin (PEG/RBV-DOT) is more efficacious than standard DOT with weekly
provider-administered pegylated interferon (PEG-DOT) and self-administered ribavirin for
increasing adherence and improving HCV treatment outcomes. The investigators hypothesize
that PEG/RBV-DOT is associated with increased adherence and rates of sustained viral
response compared with PEG-DOT.
Inclusion Criteria:
- HCV-infected
- receive HCV medical care at the methadone clinic
- plan to initiate HCV treatment on-site within the next 3 months
- psychiatrically stable as determined by HCV treatment provider and/or on-site
psychiatrist
- attend the methadone clinic between three and six days per week to receive methadone
- stable dose fo methadone for two weeks prior to the baseline visit
Exclusion Criteria:
- unable or unwilling to provide informed consent
- currently receiving HCV treatment
- primary HCV care provider does not agree to their participation in the trial
- psychiatrically unstable
We found this trial at
1
site
Click here to add this to my saved trials